Holen Sie sich die Stockscreener-App
7.31
1.81%
0.13
Vorhandelsmarkt:
7.32
0.01
+0.14%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NEO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$7.18
Offen:
$7.24
24-Stunden-Volumen:
1.24M
Relative Volume:
0.58
Marktkapitalisierung:
$1.01B
Einnahmen:
$628.25M
Nettoeinkommen (Verlust:
$-78.55M
KGV:
-11.79
EPS:
-0.62
Netto-Cashflow:
$-29.73M
1W Leistung:
+4.28%
1M Leistung:
+0.41%
6M Leistung:
-55.64%
1J Leistung:
-47.30%
1-Tages-Spanne:
$7.1392
$7.41
1-Wochen-Bereich:
$6.97
$7.44
52-Wochen-Spanne:
$6.08
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Firmenname
Neogenomics Inc
Sektor
Branche
Telefon
(239) 768-0600
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Vergleichen Sie NEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
7.31 | 1.01B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
405.46 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.54 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
536.34 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
118.01 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
157.59 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-15 | Eingeleitet | Guggenheim | Neutral |
| 2025-04-30 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Eingeleitet | Jefferies | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-08-21 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-02-24 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Hochstufung | Needham | Hold → Buy |
| 2022-08-26 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Herabstufung | Needham | Buy → Hold |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-03-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-29 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Fortgesetzt | Stephens | Overweight |
| 2021-12-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-25 | Fortgesetzt | Needham | Buy |
| 2021-02-25 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-12-11 | Fortgesetzt | BTIG Research | Buy |
| 2020-10-28 | Bestätigt | Needham | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-28 | Eingeleitet | Guggenheim | Buy |
| 2020-07-29 | Bestätigt | Needham | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Overweight |
| 2020-03-02 | Fortgesetzt | Craig Hallum | Buy |
| 2020-02-28 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-01 | Bestätigt | Needham | Buy |
| 2019-03-29 | Bestätigt | Needham | Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-10-24 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-02 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-08-24 | Eingeleitet | Gabelli & Co | Buy |
| 2016-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Neogenomics Inc Aktie (NEO) Neueste Nachrichten
NeoGenomics' Market Cap Drops To US$954m Leaving Insiders With Losses - simplywall.st
NeoGenomics Requests to Dismiss Class Action Filed by Investors - TradingView
NeoGenomics drops as sequential revenue decline leads to Q1 miss - MSN
NeoGenomics Schedules its First Quarter 2021 Earnings Release for May 5, 2021 - ACCESS Newswire
Investor Calendar Invites You to the NeoGenomics Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Tuesday March 1, 2016 - ACCESS Newswire
NeoGenomics at William Blair Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
NeoGenomics at William Blair Conference: Strategic Growth and Innovation - Investing.com Australia
Where are the Opportunities in (NEO) - news.stocktradersdaily.com
Cancer Tumor Profiling Market Rises with Demand - openPR.com
Liquid Biopsy Market for Cancer Detection, cfDNA & CTC Analysis | - openPR.com
Fort Myers-based NeoGenomics to unveil new cancer diagnostics at ASCO 2025 - Gulfshore Business
NeoGenomics unveils new oncology diagnostics at ASCO 2025 By Investing.com - Investing.com South Africa
Neogenomics director Kelly buys $38,000 in common stock - Investing.com Australia
Neogenomics director Kelly buys $38,000 in common stock By Investing.com - Investing.com Nigeria
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025 - BioSpace
NeoGenomics unveils new oncology diagnostics at ASCO 2025 - Investing.com
NeoGenomics Approves Key Proposals at Annual Meeting - TipRanks
D. E. Shaw & Co. Inc. Trims Stock Position in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
BNP Paribas Financial Markets Sells 35,979 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Rating of “Hold” from Analysts - Defense World
NeoGenomics introduces c-MET companion diagnostic for NSCLC - Yahoo Finance
Take Care Before Jumping Onto NeoGenomics, Inc. (NASDAQ:NEO) Even Though It's 25% Cheaper - simplywall.st
NeoGenomics launches rapid c-MET diagnostic test for NSCLC - Investing.com Australia
NeoGenomics launches rapid c-MET diagnostic test for NSCLC By Investing.com - Investing.com South Africa
Neogenomics Launches C-Met Cdx Assay To Guide Treatment Decisions For Advanced Non-Small Cell Lung Cancer - marketscreener.com
NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer - Business Wire
Ameriprise Financial Inc. Reduces Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
Envista, NeoGenomics, Acadia Healthcare, Astrana Health, and Hims & Hers Health Stocks Trade Down, What You Need To Know - Yahoo Finance
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market - openPR.com
NeoGenomics to Participate in Upcoming June Investor Conferences - Bluefield Daily Telegraph
Leading Oncology Testing Firm NeoGenomics Announces Key June Investor Conference Schedule - Stock Titan
3 Healthcare Stocks with Mounting Challenges - FinancialContent
Guggenheim Begins Coverage on NeoGenomics (NASDAQ:NEO) - Defense World
NeoGenomics To Present At 39th Annual William Blair Growth Stock Conference - ACCESS Newswire
NeoGenomics opposes US PTAB discretionary denial, citing public health concerns - MLex
Guggenheim Begins Coverage of NeoGenomics (NEO) with Neutral Stance | NEO Stock News - GuruFocus
Guggenheim Initiates Coverage on NeoGenomics With Neutral Rating - marketscreener.com
NeoGenomics (NEO) Initiated with Neutral Rating by Guggenheim Analyst | NEO Stock News - GuruFocus
NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Tower Research Capital LLC TRC - Defense World
NEO Q1 Earnings Call: Sales Growth, Pharma Headwinds, and Pathline Integration Shape Outlook - Yahoo Finance
NeoGenomics (NASDAQ:NEO) Upgraded to Hold at StockNews.com - Defense World
Insider Buying: Stephen Kanovsky Acquires Shares of NeoGenomics Inc (NEO) - GuruFocus
Chief Financial Officer of NeoGenomics Jeffrey Sherman Buys 14% More Shares - Yahoo Finance
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in oncology using the UG 100 sequencing platform - SelectScience
NeoGenomics, Inc. to Host Earnings Call - ACCESS Newswire
Insider Buying: Neil Gunn Acquires Shares of NeoGenomics Inc (NE - GuruFocus
Finanzdaten der Neogenomics Inc-Aktie (NEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neogenomics Inc-Aktie (NEO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KANOVSKY STEPHEN M | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
52,344 |
| Kelly Michael Aaron | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
44,009 |
| TETRAULT LYNN A. | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
73,652 |
| Floegel Elizabeth | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
23,590 |
| Gunn Neil | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
28,100 |
| Zook Anthony P. | Chief Executive Officer |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
23,590 |
| Perez David Brian | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
33,890 |
| Kelly Michael Aaron | Director |
May 27 '25 |
Buy |
7.60 |
5,000 |
38,000 |
5,000 |
| Olivo Alicia C | EVP, GC & Business Development |
May 11 '25 |
Option Exercise |
0.00 |
6,503 |
0 |
51,204 |
| Sherman Jeffrey Scott | Chief Financial Officer |
May 11 '25 |
Option Exercise |
0.00 |
13,005 |
0 |
171,499 |
1.01%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):